Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivir takes $45 million up front for Xerese and hands over full US rights to Meda

This article was originally published in Scrip

Executive Summary

Medivir has renegotiated the terms of its commercial partnership with Meda for the cold sore (recurrent herpes labialis) treatment Xerese (5% aciclovir plus 1% hydrocortisone). It will now receive a $45 million payment from Meda in return for transferring all rights to the product in the US, Canada and Mexico. Meda launched the product in the US in February this year where it is available on prescription and Medivir currently receives a double digit royalty on Meda's sales in this market. Their collaboration on the product was signed in February last year.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013504

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel